A simplified cryopreservation method for bone marrow (BM) and peripheral blood progenitor cells (PBPC) was utilized in hematopoietic cell transplantation of 213 patients with hematological or solid neoplasms after ablative chemotherapy (187 with peripheral blood progenitor cells and 26 with bone marrow). Cells were cryopreserved, after addition of autologous fresh plasma with DMSO, without HES, by freezing to ؊80؇C in a methanol bath and non-programmed freezer. For the patients autotransplanted with PBPC, the median period necessary for recovery of more than 0.5 × 10 9 /l granulocytes was 11 days (range 6-44), and 15 (8-204) days were required to obtain more than 20 × 10 9 /l platelets. For the patients autotransplanted with BM, the median period necessary to recover Ͼ0.5 × 10 9 /l granulocytes was 12 days (range 9-33), and 24 (12-57) days to obtain more than 20 × 10 9 /l platelets. These results support this method as being very effective in achieving high-quality cryopreservation. The procedure, which uses a non-programmed freezer, simplifies and reduces enormously the cost of the technical measures currently in use, enabling its adoption in almost any clinical oncological institution.
puterized freezing programs. [1] [2] [3] [4] Experience using direct or non-programmed freezing systems for hemotopoietic progenitor cells and their transplant is less widespread. [5] [6] [7] [8] [9] [10] [11] In this article, we summarize our experience using a simple, non-programmed freezing method for the transplant of hematopoietic cells in patients with neoplastic disease. Two different in vitro experiments were designed to analyze the reproducibility and the effect of the methanol bath on freezing rates. Finally, a limited comparative study of in vitro cell viability following programmed and non-programmed freezing is also presented.
Materials and methods

Cooling rates
In order to analyze the reproducibility of the cooling rates with the methanol system and the impact of this technique on the standardization of the freezing, two different in vitro experiments were performed.
In the first (Figure 1 ), four different bags containing 160 ml of hematopoietic cells in 10% DMSO and autologous plasma were cryopreserved using a mechanical freezer at Ϫ80°C in a methanol bath as previously described. Temperatures were registered minute by minute for the first 35 min and every 5 min thereafter, for 80 min.
In the second (Figure 2 ), cooling rates with and without the methanol bath with bags containing 26, 80 and 132 ml each of hematopoietic cells in 10% DMSO and autologous plasma were used. Bags were cryopreserved in a mechanical freezer at Ϫ80°C. Temperature profiles in both experiments were obtained using a 51 K/J Thermocouple placed into the bags. The mean values of several experimental procedures were considered to elaborate the final picture.
Patients
Between July 1989 and August 1990, a pilot group of six patients with different hematological diseases were successfully autotransplanted using bone marrow progenitor cells which were treated by non-programmed freezing. Since July 1992, this freezing system has been used systematically for most transplants performed in our center, both 1  4  7  10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 with PBPC (187 autotransplants) and BM (20 patients), in adult and pediatric patients ( Table 1) . The pilot group was composed of six patients diagnosed with acute leukemia.
The group of PBPC autotransplanted patients was composed of 187 patients with several neoplastic diseases, and the group of bone marrow autotransplanted patients was made up of 20 patients, both groups with several neoplastic diseases.
Patients received different marrow-ablative regimens, depending on their diagnoses. [12] [13] [14] [15] [16] [17] After myeloablative therapy, adult patients were nursed in single rooms using simple reverse isolation measures, and pediatric patients were isolated in positive pressure rooms. PBPC or BM were reinfused after thawing on day 0. Red blood concentrates (RBC) were transfused when the hemoglobin value was less than 10 g/dl and random platelet transfusions were employed when platelet count was less than 15 × 10 9 /l or bleeding had occurred. Filgrastim (5 g/kg body weight), administered daily as a single subcutaneous injection, was initiated on day +1 (47 patients), +2 (90 patients) or +5 (70 patients), and was continued until the absolute neutrophil count was greater than 1.5 × 10 9 /l. The pilot group received no colony stimulator factors.
Collection of peripheral blood and bone marrow stem cells
Between July 1992 and January 1997, a total of 438 leukaphereses were performed. Informed consent was obtained from all patients. Harvest was scheduled independently of the date of the last chemotherapy administered, with a minimum period of 1 month between the last therapy session and harvest.
PBPC were mobilized using rhG-CSF (Filgrastim; Amgen, F Hoffman-La Roche Ltd, Basel, Switzerland); 5 g/kg were administered subcutaneously (s.c.) in the first 97 patients and 10 g/kg in the last 90 on the 4 days prior to harvest and during the period of the procedure. Harvesting was terminated when total mononuclear cells (MNC) obtained reached 7 × 10 8 /kg body weight in the first 63 patients and 5 × 10 8 /kg body weight MNC and/or 2.5 × 10 6 /kg CD34 + cells in subsequent cases. Prior to the procedure, a 13.5 F double lumen Hickman's catheter was placed radiographically by puncture technique. 18 Harvesting was performed with two types of cell separators (COBE-Spectra; Cobe Laboratories, Lakewood, CO, USA and Fenwal CS-3000/CS-3000-plus; Baxter Health Care Corporation, Fenwal Division, Deerfield, IL, USA). For pediatric patients less than 20 kg body weight, the harvesting system was previously filled with a unit of red blood cells (irradiated and filtered, filter RC-50E; Pall Biomed Prod. Co., East Hills, NY, USA) and saline with albumin. The mean bone marrow volume collected was 0.58 Ϯ 0.34 l (0.13-1.1, with a median of 0.52 l).
Bone marrow cells were collected from the iliac crests under general anesthesia in double standard bags for red blood cell collection with preservative-free heparin, as previously described. 19 Marrow was concentrated and depleted of red cells using a cell separator, as previously described, 20 or by centrifugation.
Flow cytometry
An estimate of the progenitor cell number in the inoculum was determined by analysis of the CD34 + mononuclear cells, employing a direct immunofluorescence flow cytometry assay. 21 
CFU-GM
Granulocyte-macrophage colony-forming units (CFU-GM) were assayed after thawing for the comparative analysis of programmed vs methanol bath freezing. The mononuclear fraction was washed twice and the pellet was resuspended and adjusted to a final concentration of 5 × 10 5 cells /ml. After the last wash, 1 ml of the cells was mixed with 3 ml of CFU culture medium (Stem Cell CFU Kit; Baxter Immunotherapy Division).
The cell/methylcellulose suspension was plated in triplicate 1 ml cultures into Petri dishes (Nunc, Kamstrup, Roskilde, Denmark) and incubated at 37°C in a humidified 5% CO 2 atmosphere. The culture plates were scored by inverted microscopy on day 14 for CFU-GM (a colony consists of at least 40 cells).
Preparation of cryoprotective solution
Autologous plasma, obtained during the harvesting procedure, was mixed with DMSO to a concentration of 20% DMSO. The addition of DMSO to the plasma bag was performed at 1°C (water with melting ice).
Cryopreservation
The PBPC and BM obtained were heparinized with 5 units/ml of additive-free sodium heparin (Heparina; Laboratorio Farmaceutico Rovi, Madrid, Spain) and distributed in several Teflon-Capton bags (Type DF 700; Gambro Dialysatoren and CoKG Hechingen, Germany). The 20% DMSO in autologous plasma mixture was added steadily to the PBPC/BM solution in an ice bath, with gentle agitation. Equivalent volumes of DMSO/plasma and PBPC/BM solutions were mixed, to obtain a 10% final DMSO concentration over a controlled period of less than 15 min.
After removing air and heat sealing the bags, they were placed in standard aluminium packs and immersed in a plastic container with 3 l of previously cooled (0°C) 95% methanol. Finally, the container was placed in a mechanical freezer at Ϫ80°C (REVCO, UFRC 1386 U-O-B, Ashville, NC, USA). After 24 h, the pack was placed in liquid nitrogen for long-term storage.
The methanol was renewed for each cryopreservation procedure to avoid a possible microbiological contamination and changes in its cryogenic point due to evaporation.
For the comparative study a programmed freezing system was used: cryopreservation was performed in a programmable freezer (Cryoson TRA-14; Carburos Metálicos, Barcelona, Spain). Cells were introduced into a chamber cooled to 4°C and were equilibrated for 10 min, then they were frozen at a Ϫ1°C/min rate until reaching Ϫ20°C and then at Ϫ8°C/min until Ϫ120°C.
Thawing and infusion
Cells were thawed by rapid heating of the cryopreservation bags, by immersion in a 40°C water bath. The bags were thawed one by one, and a new bag was not thawed until the last bag had been completely infused. Before infusion, 3 ml of the thawed solution was obtained for viability, cytologic and microbiological control tests. Viability was assessed by trypan blue exclusion. Immediately after thawing, the PBPC were rapidly infused by a Hickman's central line. Blood pressure and electrocardiograph were monitored during the procedure.
Statistical analysis
All data were collected using a custom-adapted File-Maker Pro (Macintosh, Apple Computer, Madrid, Spain) database and analyzed with Stat-View SE + Graphics software (Macintosh). The correlation between variables was evaluated with the Spearman rank correlation coefficient. The differences among the means of variables were analyzed using the ANOVA test.
Results
Cooling rates
In the first experiment, similar and reproducible cooling rates were obtained. The mean freezing velocity was 1.2°C/min (Figure 1) .
In the second, a clear impact of the use of the methanol bath was observed: the cooling rates obtained with it are constant independently of the variable volumes used (Figure 2 ).
Thawing and infusion (Table 2)
Cell viability was high in all cases and no correlation exists between viability after thawing and final cell concentration in the cryopreservation bags or duration of conservation.
The number of CD34 + cells for patients autotransplanted with PBPC was 4.4 Ϯ 4.5 × 10 6 /kg body weight (0.3-29.7), with a median of 3.2.
The number of CD34 + cells for patients autotransplanted with BM was 7.9 Ϯ 7.7 × 10 6 /kg body weight (0.8-21.5), with a median of 4.9.
In 11 PBPC cases, a comparative study of in vitro viability after thawing using a programmed freezing method vs methanol cryopreservation was carried out. The numbers of CFU-GM were comparable using the two methods (P = 0.0018) ( Table 3) . Table 2 Thawing and infusion Spearman rank correlation coefficient 0.31 (P = 0.0018). CFU-GM = granulocyte-macrophage colony-forming units; num = numerous.
Hospital course and toxicity after PBPC and BM autograft
Five patients from the pilot group are alive and in complete remission. All but one achieved a complete engraftment (defined as Ͼ1.5 × 10 9 /l granulocytes, Ͼ10 g/dl Hb and Ͼ50 × 10 9 /l platelets without stimulators factors or transfusional support). One patient (a non-Hodgkin lymphoma) did not reach more than 50 × 10 9 /l platelets, but is transfusion support free and alive.
Data on hematopoietic recovery, support measures and outcome of the rest of the patients are shown in Table 4 . Complete engraftment was evaluated on day +100 post transplant and was achieved in all cases but one with BM and in the majority of PBPC patients. In the PBPC group, 14 patients died before day +100 post-autograft. Eight died in the first 15 days after the procedure, reaching more than 1 × 10 9 /l granulocytes in two cases, but without platelet engraftment in any case. Of the other six patients, five achieved complete engraftment and later died due to relapse and one with myeloid acute leukemia relapsed without granulocyte or platelet recovery. Only nine PBPC patients and one BM patient displayed a poor or incomplete engraftment at day +100 post transplant. Seven of the PBPC group (three myeloid acute leukemias, one with multiple myeloma, one with ovarian cancer, one with chronic myeloid leukemia and one with breast carcinoma) eventually relapsed and died. One patient with multiple myeloma was alive, in partial remission and on transfusion support. Finally, the ninth PBPC patient, diagnosed with a nonHodgkin lymphoma, achieved a complete engraftment as late as 16 months after the procedure. The only BM patient with poor engraftment at day +100 (a non-Hodgkin lymphoma) achieved normal peripheral blood counts in the fourth month post transplantation.
Granulocyte recovery over 0.5 × 10 9 /l was rapid for PBPC and BM patients (median 11 days, range 6-44, and median 12 days, range 9-33, respectively). The median lapse time in aplasia (days between less than 500 granulocytes and more than 500 granulocytes) was 9 days for the PBPC patients and 11 days for BM patients. In the PBPC group, the mean time required for recovery of more than 20 × 10 9 /l platelets was 24 Ϯ 18 days (range ). The number of platelet transfusions ranged from 0 to 48 (median 4).
Sixteen patients died during the transplantation process (7.5%).
Discussion
Mechanical non-programmed freezing of bone marrow 5, 6 and PBPC [7] [8] [9] [10] [11] has been described previously, and is a technically simple and much more economical system. Nonetheless, two obstacles prevent its generalized use: (1) the 516 difficulty in standardization and (2) the need for testing the clinical and biological results in large numbers of patients, to support the scientific basis of programs using these methods.
The first group was formed with six patients transplanted in the period 1989-1990 with bone marrow; 7 years later, five of these patients are alive and four maintain a complete graft. The stability of these transplants and the apparently good preliminary results motivated continuation of the method, and transplants using the non-programmed freezing system were performed in 207 additional patients who form the remainder of this series.
One of the principal obstacles in 'non-programmed freezing' is an adequate system of standardization, and one factor to be considered here is the difference in sample volume size, since it has been shown that the freezing rate of a sample varies depending on its volume. Clark et al 6 showed that the cooling rate depends on the volume being frozen. Here, the bag is introduced into a three-liter methanol bath. Thus, we do not refer to the freezing of a small volume of cells; in physical terms, a 3-l methanol bath is being cooled which contains the product in its interior. Cooling a large volume enables the freezing of variable volumes of PBPC/BM, and reproducible cooling speeds are obtained without the use of a rate controller (Figure 2 ). The inclusion in the methanol bath makes possible the standardization of the freezing system.
The cryopreservative solutions used may also contribute to the disparities among results reported. This aspect has been simplified here, using a cryopreservative solution consisting only of autologous plasma with dimethylsulphoxide to give a final concentration, after mixing, of 10%. The only caution required is detection of cryoglobulins in this plasma, mainly in patients with myeloma or immunocytoma. If cryoglobulins are present, we must use isogroup plasma. The absence of hydroxyethyl starch (HES) in the cryopreservative solution in our method is one of its relevant points. We have demonstrated that is possible to obtain adequate viability of cells using autologous plasma and DMSO exclusively, obtaining a remarkable simplification of the technique used by other authors. [5] [6] [7] Moreover, recent data questioned the contribution of HES in cryopreservation.
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In 11 patients, simultaneous samples were obtained in the same apheresis product, and submitted to both non-programmed freezing in methanol at Ϫ80°C and to programmed freezing with a Cryoson. The CFU-GM analysis performed after freezing and thawing showed no differences between the two methods. This has been demonstrated clinically by Takaue et al 10 in a small number of pediatric patients using another non-programmed freezing method.
The clinical results did not differ substantially from those obtained in programmed cryopreservation, save for a slight delay in platelet recovery. This could be explained by the low G-CSF dose used in our series to mobilize PBPC 23 or for the use of G-CSF after transplantation.
The mortality in our series, although it includes a wide range of ages, pathologies and clinical pretransplant status (including patients with advanced stages), did not exceed 8% and is thus comparable to other series reported using programmed freezing. 3 In a few cases, a complete engraftment was not achieved on day +100. In these cases, the number of CD34 cells infused was similar to the rest of the series. Possibly, other factors such as the nature of disease, conditioning regimens utilized or multiple chemotherapies used previously to transplant, 24 could explain the incomplete engraftment in these patients.
In conclusion, we present 213 BM-or PBPC-transplanted patients for whom it appears that non-programmed cell freezing at Ϫ80°C in a methanol bath can be an easily standardized system, yielding good clinical results. The cryoprotective solution with autologous plasma and DMSO is simple and effective.
The system appears to be simple and efficient, but further studies in other centers will be necessary to confirm these results.
